Tenderwize
Zurück zur Suche

Open-house discount agreements for Naproxen

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 05, 2026 · 8 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Naproxen, ATC M01AE02

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

For paper submissions, advance fax/scan/email transmission is only deadline-preserving if the original paper documents...

Only pharmaceutical companies are eligible as potential contract partners.

Submission deadline in 8 days

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Non-exclusive open-house discount agreements for pharmaceutical products concerning Naproxen, ATC M01AE02.
  • Supply contract model for a medicinal product discount agreement under § 130a(8) SGB V, as described in the notice.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for Naproxen (ATC M01AE02) offered by AOK Bayern to all interested pharmaceutical companies that meet the stated suitability requirement. This is explicitly described as a non-exclusive, non-negotiated accession model, not a classic competitive award procedure. No contract value is stated. Submission is possible electronically with a qualified electronic signature or in paper form, with strict monthly cut-off rules and a final deadline of 05.09.2026.

Risiken

For paper submissions, advance fax/scan/email transmission is only deadline-preserving if the original paper documents...

Only pharmaceutical companies are eligible as potential contract partners.

Submission deadline in 8 days

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • The signatory's authority must be evidenced by the commercial register extract; otherwise a power of attorney must be provided.

Administrative

  • Submit a signed contract, the completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and the signed declaration of reliability.
  • Submissions must be either handwritten on paper or electronically with a qualified electronic signature.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house discount agreements for Naproxen

Single lot covering non-exclusive open-house pharmaceutical discount agreements for the active substance Naproxen (ATC M01AE02). The lot is for supplies and performance is in Germany, Bavaria (DE212). The notice states that all interested pharmaceutical companies meeting the suitability requirement may join on identical terms. Lot information comes from structured data and notice text.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Oct 2024 - Oct 2026

Kategorie

Pharmaceutical products

Frist

Deadline Sep 05, 2026

Vergabedetails

Veröffentlichungsdatum
16 Sep 2024
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
558157-2024

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30